Syntekabio Unveils AI-Powered 'Develop Now, Pay Later' Model to Accelerate Drug Discovery
TL;DR
Syntekabio's 'Develop Now, Pay Later' offer minimizes risk, saves time and costs, and increases success rate for drug development companies.
Clients can submit target protein for analysis via the STB LaunchPad program with no upfront costs, paying only after validated results are obtained.
Syntekabio's mission is to deliver safer and more effective therapies to patients, supporting groundbreaking drug development work and reducing risk for clients.
Syntekabio's AI accesses over 10 billion known compounds and 1,400 in vitro/in vivo compatible drug targets, revolutionizing the drug discovery and development process.
Found this article helpful?
Share it with your network and spread the knowledge!
Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI)-based drug development company, has introduced a new 'Develop Now, Pay Later' offer designed to minimize risk, save time, and reduce costs for companies developing novel therapies. This initiative allows pharmaceutical and biotechnology firms to test the validity of target proteins without incurring any upfront costs. If a project demonstrates viability, Syntekabio employs its STB LaunchPad program, powered by the proprietary AI-driven DeepMatcher® technology platform, to deliver hits, optimized leads, and IND-enabled candidates.
Jongsun Jung, PhD, CEO of Syntekabio, stated, “We want our clients to achieve their goal of bringing safer and more effective therapies to patients. Thus, our mission at Syntekabio is to deliver to our clients first-in-class or best-in-class compounds, fast. We strongly believe in the capability of our technology and so, to further invest in our clients’ success, we have introduced our Develop Now, Pay Later model to support groundbreaking drug development work and reduce the risk for our clients at the outset.”
The 'Develop Now, Pay Later' model is a significant step in making drug discovery more optimized and lower-risk. Clients can first take advantage of a complimentary feasibility study to determine project viability. The next step involves submitting any target protein for analysis via the STB LaunchPad program, with no upfront fees. Payment is only required once validated results are obtained.
Syntekabio's AI accesses over 10 billion known compounds and 1,400 in vitro/in vivo compatible drug targets, covering over 70% of human diseases. This technology is fueled by the AI Bio-Supercom Center, which houses an extensive infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs. The company's advanced proprietary tools are designed to accelerate the drug discovery and development process efficiently.
For more information about Syntekabio, STB LaunchPad, and the 'Develop Now, Pay Later' model, please click here.
Curated from News Direct
